Quantum BioPharma's $12.22M Cash and Digital Assets Fuel Lucid-MS Phase 2 Trial

Quantum BioPharma reported $12.22 million in cash and digital assets and advancing its Lucid-MS Phase 2 trial, signaling improved financial health and clinical progress for the multiple sclerosis treatment.

Chicago Metrowire Staff
••Healthcare
Quantum BioPharma's $12.22M Cash and Digital Assets Fuel Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, showing combined cash and digital assets of $12.22 million, up from $4.12 million at year-end 2025, excluding restricted digital assets. The improvement in liquidity, alongside a 24% year-over-year reduction in third-quarter operating expenses to $3.56 million and a 26% narrower nine-month net loss of $17.32 million, positions the company to advance its lead drug candidate, Lucid-MS, into a Phase 2 clinical trial for progressive multiple sclerosis.

The financial results matter because they indicate that Quantum BioPharma has strengthened its balance sheet while cutting costs. Shareholders’ equity increased 91% to $9.77 million, and working capital rose to $5.47 million from $420,000. The company also reduced its operating cash use by 21% in the first nine months of 2026 and lowered notes payable to $300,000 after repaying $1 million in debt. Management stated that its cash and digital asset holdings are sufficient to support planned operations over the next 12 months, removing near-term financing risk as the company invests in its clinical program.

That clinical program took a significant step forward after quarter-end. Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 trial of Lucid-MS. The agreement follows U.S. Food and Drug Administration clearance of the company’s Investigational New Drug application in August 2026. Lucid-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Phase 2 trial is designed to evaluate the compound in patients with progressive forms of the disease, which currently have limited treatment options.

For investors, the combination of a stronger cash position, lower operating expenses and a clear clinical milestone reduces the financial overhang that often weighs on small biotech companies. The digital asset component of the company’s holdings, valued at $8.66 million, also adds a non-traditional source of liquidity, though its value can be volatile. The full press release is available at https://ibn.fm/GJ1ER, and additional information about Quantum BioPharma can be found at Quantum BioPharma (NASDAQ: QNTM). The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM, and the original release was distributed by NEWMEDIAWIRE.

Quantum BioPharma is a biopharmaceutical company building a portfolio of assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The company also invented UNBUZZD and retains a 19.84% ownership stake in Unbuzzd Wellness Inc., along with royalty rights on sales. The advancement of Lucid-MS into Phase 2 testing represents a key value inflection point for Quantum and could provide a new therapeutic approach for progressive multiple sclerosis if the trial succeeds.

Blockchain Registration

QR Code for Blockchain Registration